other services

API Occupational Hygiene Monitoring
YOU ARE HERE Home Industry Applications API Occupational Hygiene Monitoring INDUSTRY APPLICATIONS Amino Acid Testing Animal Healthcare Products Extractables and Leachables Testing Pharmaceutical Development Pharmaceutical Manufacturing API Occupational Hygiene Monitoring Bone Substitute Medical Device Nicotine and TPD2 Support For more information: Call: +44 1274 326073 Email: answers@agenda1.co.uk API OCCUPATIONAL HYGIENE MONITORING Exposure to APIs released into the [...]

For more information:
Call: +44 1274 326073
Email: answers@agenda1.co.uk

Solent_Top_09052014

High throughput formulation solubility screening

The Imperative

Often, early stage approaches to solubilising a drug substance (for example using DMSO) are not appropriate for a dose formulation that needs to be suitable for pre-clinical and clinical studies. Identification of a formulation approach designed to maximise drug loading and exposure is a prerequisite. Identifying options suitable for oral, parenteral or transdermal administration at an early stage brings time-saving and cost benefits to the entire programme.

The Solution

Developed and delivered by Agenda1, we can provide a rational and innovative formulation screening platform, Excipient Solubility Screening. The foundation of Excipient Solubility Screening is its utilisation of a proprietary preformulation matrix, comprising a wide variety of combinations of liquid-based GRAS/IIG formulation excipients approved for preclinical and clinical use (including pH adjustment, co-solvents, micro-emulsions, SEDDS, oils, lipids and cyclodextrins). With a unique evaluation method it is possible to provide information on the solubility and stability of a drug substance in a wide range of excipients. Agenda 1 can then provide advice on the recommended solubility enhancement approach, which is designed to produce an overview to point to further formulation development steps (e.g. absolute solubility determination and in-use stability).

Benefits of the Excipient Solubility Screening screening platform include:

  • Recommendations for formulations designed for maximum drug loading and exposure
  • Identification of formulations suitable for either oral or parenteral administration
  • Small sample volumes and API masses are required
  • Rapid delivery of successful formulations for in vivo investigations
  • Supporting stability testing and method development (e.g. HPLC) to match planned study timelines

Identifying excipient options suitable for oral, parenteral or transdermail administration at an early stage brings time-saving and cost benefits to the entire drug development programme.